In March 2026, Australian startup Symex Labs unveiled a wearable patch biosensor developed in collaboration with the University of Melbourne that uses microneedles to continuously monitor progesterone and estradiol levels in interstitial fluid — the clear fluid just beneath the skin. The device translates the electrical activity generated when progesterone molecules bind to the probe's surface into hormone readings sent directly to a clinic's monitoring system, potentially eliminating the frequent and painful blood draws that IVF patients currently endure throughout treatment cycles.

Why It Matters

Hormone monitoring is one of the most friction-heavy aspects of fertility treatment and reproductive health management. IVF patients routinely face 10 or more blood draws per cycle, each requiring a clinic visit. A wearable that delivers continuous, real-time hormone data could reduce clinic visits, lower costs, and give patients and providers far richer data for treatment decisions. If Symex's microneedle approach validates clinically, it could do for reproductive endocrinology what continuous glucose monitors did for diabetes — and open a substantial new hardware category within femtech.

Co-founded by University of Melbourne alumni Edgar Charry and Muhammad Umer — both of whose partners have personal experience with infertility — Symex Labs is now conducting a world-first clinical study at Monash IVF to establish baseline hormone levels in interstitial fluid by benchmarking them against concentrations measured in blood samples. A first in-human pilot study is expected within 12 months, with commercialization targeted for early 2028. The project has secured $2.5 million in funding from the Australian federal government, the University of Melbourne's Genesis fund, Monash IVF, RMIT, and Breakthrough Victoria.

Beyond IVF, the technology has significant potential for broader reproductive and hormonal health monitoring. Co-founder Muhammad Umer noted the biosensor could transform "PCOS management, perimenopause and menopause symptom management, where continuous hormone insight can replace today's indirect, symptom-based tracking." If successful, the device would bring continuous glucose monitor-style convenience to hormone tracking — a category where patients have had to rely on infrequent blood snapshots or unreliable symptom diaries.

Sources

Update — 2026-03-22

Initial entry — story first created.